Retatrutide (LY3437943) Compound Combinations: Dual/Triple Agonist Formulations and Research Trends

Product Deep Dive | 2026-07-09 | 10 min read

A 2026 research guide to retatrutide (LY3437943) compound combinations: GLP-1/GIP/GCGR triple agonism, amino acid sequence, synthesis notes, formulation combinations, and peer-reviewed research landscape.

Retatrutide: the first clinical triple agonist

Retatrutide (LY3437943), developed by Eli Lilly, is the first peptide in clinical development with proven GLP-1, GIP, and glucagon receptor (GCGR) triple agonism. The TRIUMPH-1 Phase 2 trial produced 24.2% body weight reduction at 48 weeks — a result that redefined expectations for the GLP-1 class and made retatrutide the most closely watched metabolic peptide entering Phase 3.

Triple agonism: mechanism

Three receptors activated:

  • **GLP-1 receptor** — satiety, insulin secretion, gastric slowing
  • **GIP receptor** — enhanced insulin secretion, food intake regulation
  • **Glucagon receptor** — energy expenditure, thermogenesis, lipolysis

The triple mechanism means each receptor contributes a distinct metabolic pathway. GLP-1 drives the appetite suppression and glycemic control. GIP enhances the insulin response and may modulate the reward pathway for food. GCGR adds the thermogenic and lipolytic component that distinguishes retatrutide from tirzepatide.

The GIPR component of retatrutide is engineered with a different bias than tirzepatide's GIPR — retatrutide's GIPR activation is lower relative to GLP-1R, which may reduce nausea and improve tolerability.

Amino acid sequence

Retatrutide is a modified human GLP-1/GIP hybrid analog with 39 amino acids. Key modifications:

  • **Aib at position 2** — DPP-4 resistance
  • **Position 20 or 24 Lys** — fatty diacid conjugation site
  • **C18 fatty diacid chain** — albumin binding for weekly dosing
  • **GIP sequence incorporation** — the GIPR-active portion is embedded in the GLP-1 scaffold

Confirm the exact sequence and modification site with the supplier's specification sheet.

Synthesis complexity

Retatrutide is one of the most structurally complex GLP-1 analogs in development. The triple agonism requires:

  • Precise placement of GLP-1, GIP, and glucagon active sequences within a single peptide
  • Non-natural amino acid incorporation (Aib)
  • Site-specific fatty diacid conjugation
  • Triple purification to separate GLP-1R, GIPR, and GCGR-related impurities

Low-quality lots risk misfolded sequences, wrong conjugation site, or GIPR/GCGR potency loss. Always verify MS data against theoretical mass and request the HPLC chromatogram.

Compound combination research trends

Research programs are exploring:

  • **Retatrutide + GLP-1 combinations** — fixed-ratio combinations with oral GLP-1 agents for enhanced glycemic control
  • **Retatrutide + amylin analogs** — additive satiety and gastric slowing effects
  • **Retatrutide + SGLT2 inhibitors** — complementary cardiometabolic mechanisms
  • **Retatrutide + GDF15 agonists** — exploring nausea mitigation through different appetite pathways

These combinations are in preclinical or Phase 1 stages. None are commercially available yet.

COA specification for retatrutide research peptide

| Test | Method | Acceptance Criterion | | --- | --- | --- | | Appearance | Visual | White to off-white lyophilized powder | | HPLC Purity | RP-HPLC, 220nm | ≥95% | | MS (ESI) | Mass spectrometry | ±0.5% of theoretical m/z | | Endotoxin | LAL kinetic chromogenic | <1.0 EU/mg | | Water content | KF titration | <3% | | Residual solvents | GC headspace | Within ICH Q3C limits |

Additional characterization for triple agonism:

  • Receptor binding assay data (GLP-1R, GIPR, GCGR) if available
  • Fatty acid substitution site verification by LC-MS/MS

Key literature

  • Jastreboff et al., N Engl J Med 2023 — Phase 2 TRIUMPH-1 primary results
  • Coskun et al., Cell Metab 2023 — triple agonism mechanism characterization
  • Eli Lilly pipeline update, 2025 — Phase 3 TRIUMPH program status

Sourcing

Retatrutide is still primarily a clinical-stage compound. Research-grade material is available from qualified peptide manufacturers with ≥95% HPLC purity, MS verification, and endotoxin testing. Request the HPLC chromatogram and confirm the fatty acid substitution site before accepting any lot.

ZePeptide supplies retatrutide for laboratory research with full COA documentation and cold-chain validated shipping.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides